<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02547558</url>
  </required_header>
  <id_info>
    <org_study_id>IndaEPOC</org_study_id>
    <nct_id>NCT02547558</nct_id>
  </id_info>
  <brief_title>Pulmonary Gas Exchange Response to Indacaterol in COPD</brief_title>
  <official_title>Pulmonary Gas Exchange Response to Indacaterol in Stable Symptomatic Chronic Obstructive Pulmonary Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the pulmonary gas exchange response to a therapeutic high dose of inhaled
      indacaterol (300 mcg) in 20 outpatients with stable symptomatic COPD B and D GOLD 2011
      groups.

      Measurements on a single day before and after 60 and 120 minutes of indacaterol will include
      arterial PO2, PaCO2 and pH. AaPO2; SaO2 (by pulse oximetry) and oxygen and carbon dioxide in
      exhaled breath, systemic arterial pressure and heart rate will also be measured/calculated.
      Cardiac output will be directly measured by bio-impedance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators hypothesize that in stable chronic obstructive pulmonary disease (COPD)
      patients the interaction between intrapulmonary and extrapulmonary determinants contributing
      to gas exchange abnormalities after indacaterol will ultimately preserve arterial oxygenation
      (primary end-point outcome).

      The study will include 20 outpatients with diagnosis of stable COPD in GOLD 2011 groups B and
      D (10 each), without frequent exacerbations (≥2 in the previous year). Patients with a COPD
      exacerbation within 3 months of study, use of long-term oxygen therapy and associated
      conditions or serious comorbidities (i.e., asthma, bronchiectasis, lung cancer and/or
      cardiovascular diseases) will be excluded.

      Each patient will be studied on a single day. All subjects will remain on their regular
      treatment for the study. Subjects will be required to withhold SABAs for at least 12 h and
      LABAs and theophylline for at least 24 h before study. During measurements, patients will
      breath room air and will be seated in an armchair. Measurements will be performed before and
      60 and 120 min after a single dose administration of indacaterol Breezhaler@ 300 mcg (1
      inhalation).

      After ensuring steady-state conditions, as assessed by stability (± 5%) of both ventilatory
      and hemodynamic variables, and by the close agreement (within ± 5%) between duplicate of
      mixed expired and arterial oxygen and carbon dioxide, a set of duplicate measurements for
      each variable will be obtained at each time point.

      Blood samples will be collected through a catheter inserted under local anesthesia into the
      radial artery. Samples of blood (5 ml) will be removed for measurement of arterial O2 tension
      (PaO2), CO2 tension (PaCO2) and pH; alveolar-arterial PO2 difference (A-a)DO2, oxygen
      saturation (SaO2), and VO2, VCO2, Ve, respiratory rate (f), systemic arterial pressure (Psa),
      and heart rate (HR) will be measured or calculated, as previously described.

      Cardiac output will be directly measured by bio-impedance. Spirometry values will be recorded
      from the history records of each patient. All measurements will be performed in the Centre de
      Diagnòstic Respiratori (CDR), Servei de Pneumologia, Institut del Tòrax, Hospital Clínic,
      Barcelona.

      The primary outcome will be the PaO2 change after indacaterol at each analysis time. Based on
      a previous study in stable severe COPD patients using nebulized salbutamol during
      convalescence of exacerbation, Polverino et al. calculated that for a significant PaO2 fall
      of the order of 8 mmHg, a sample of 6 subjects is needed; this number was increased to 20
      patients to ensure better data.

      Secondary outcomes were changes in PaCO2, pH, the calculated D(A-a)DO2 and the response of
      cardiac output.

      Results will be expressed as mean (±SEM) or median (95% CI). The effects of indacaterol on
      each of the end-point variables will be assessed by one-way repeated measures analysis of
      variance (ANOVA). Paired t tests and Pearson's correlation tests will be used as appropriate.
      All significances will be set at p&lt;0.05, without correction for multiple tests.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in PaO2 after indacaterol.</measure>
    <time_frame>60 and 120 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in PaCO2 after indacaterol.</measure>
    <time_frame>60 and 120 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in D(A-a)DO2 after indacaterol.</measure>
    <time_frame>60 and 120 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pH after indacaterol.</measure>
    <time_frame>60 and 120 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cardiac output after indacaterol.</measure>
    <time_frame>60 and 120 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Indacaterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug:
-Indacaterol, inhaled, single dose, 300 mcg
Diagnostic Interventions:
Arterial blood gases
Cardiac output
Vital signs
Exhaled breath
Spirometry</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Arterial blood gases</intervention_name>
    <description>Measured through radial arterial catheter</description>
    <arm_group_label>Indacaterol</arm_group_label>
    <other_name>PaO2</other_name>
    <other_name>PaCO2</other_name>
    <other_name>pH</other_name>
    <other_name>AaPO2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardiac Output</intervention_name>
    <description>Measured through bioimpedance: FloTrac pressure transducer (FloTrac sensor; Edwards Lifesciences) using the third-generation (3.01) FloTrac software for continuous CO display.</description>
    <arm_group_label>Indacaterol</arm_group_label>
    <other_name>CO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Vital signs</intervention_name>
    <description>As measured in clinical practice</description>
    <arm_group_label>Indacaterol</arm_group_label>
    <other_name>Respiratory rate</other_name>
    <other_name>Heart rate (HR)</other_name>
    <other_name>Systemic arterial pressure</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Exhaled breath</intervention_name>
    <description>Were recorded using a pneumotachograph (CPX/D; Med Graphics, St. Paul, MN, U.S.A.).</description>
    <arm_group_label>Indacaterol</arm_group_label>
    <other_name>Oxygen</other_name>
    <other_name>Carbon dioxide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Spirometry</intervention_name>
    <description>In a daily calibrated spirometer.</description>
    <arm_group_label>Indacaterol</arm_group_label>
    <other_name>FEV1</other_name>
    <other_name>VFC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indacaterol</intervention_name>
    <description>Indacaterol Breezhaler@ 300 mcg (1 inhalation)</description>
    <arm_group_label>Indacaterol</arm_group_label>
    <other_name>Ultra long acting beta 2 agonist</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatients with COPD diagnosis according to GOLD 2011 criteria (VEF1/CVF less than
             70%), groups B and D.

        Exclusion Criteria:

          -  Conditions or serious comorbidities (i.e., asthma, bronchiectasis, lung cancer and/or
             cardiovascular diseases).

          -  Patients with frequent exacerbations (2 or more exacerbations in the past year).

          -  History of acute COPD exacerbation in the previous 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabel Blanco, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Isabel Blanco, MD, PhD</last_name>
    <phone>+34 649539835</phone>
    <email>IBLANCO2@clinic.ub.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Clínic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabel Blanco, MD, PhD</last_name>
      <phone>+34 649539835</phone>
      <email>iblanco2@clinic.ub.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Viegas CA, Ferrer A, Montserrat JM, Barberà JA, Roca J, Rodriguez-Roisin R. Ventilation-perfusion response after fenoterol in hypoxemic patients with stable COPD. Chest. 1996 Jul;110(1):71-7. Erratum in: Chest 1997 Jan;111(1):258.</citation>
    <PMID>8681669</PMID>
  </reference>
  <reference>
    <citation>Pillet O, Manier G, Castaing Y. Anticholinergic versus beta 2-agonist on gas exchange in COPD: a comparative study in 15 patients. Monaldi Arch Chest Dis. 1998 Feb;53(1):3-8.</citation>
    <PMID>9632900</PMID>
  </reference>
  <reference>
    <citation>Whale CI, Sovani MP, Mortimer K, Oborne J, Cooper S, Harrison TW, Tattersfield AE. Effects of rac-albuterol on arterial blood gases in patients with stable hypercapnic chronic obstructive pulmonary disease. Br J Clin Pharmacol. 2006 Aug;62(2):153-7.</citation>
    <PMID>16842389</PMID>
  </reference>
  <reference>
    <citation>Kew KM, Mavergames C, Walters JA. Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013 Oct 15;(10):CD010177. doi: 10.1002/14651858.CD010177.pub2. Review.</citation>
    <PMID>24127118</PMID>
  </reference>
  <reference>
    <citation>Kew KM, Dias S, Cates CJ. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Cochrane Database Syst Rev. 2014 Mar 26;(3):CD010844. doi: 10.1002/14651858.CD010844.pub2. Review.</citation>
    <PMID>24671923</PMID>
  </reference>
  <reference>
    <citation>Khoukaz G, Gross NJ. Effects of salmeterol on arterial blood gases in patients with stable chronic obstructive pulmonary disease. Comparison with albuterol and ipratropium. Am J Respir Crit Care Med. 1999 Sep;160(3):1028-30.</citation>
    <PMID>10471636</PMID>
  </reference>
  <reference>
    <citation>Zafar MA, Droege C, Foertsch M, Panos RJ. Update on ultra-long-acting β agonists in chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2014 Dec;23(12):1687-701. doi: 10.1517/13543784.2014.942730. Epub 2014 Aug 19. Review.</citation>
    <PMID>25139313</PMID>
  </reference>
  <reference>
    <citation>Roskell NS, Anzueto A, Hamilton A, Disse B, Becker K. Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol. Int J Chron Obstruct Pulmon Dis. 2014 Jul 31;9:813-24. doi: 10.2147/COPD.S59673. eCollection 2014. Review.</citation>
    <PMID>25114521</PMID>
  </reference>
  <reference>
    <citation>Cazzola M, Segreti A, Stirpe E, Puxeddu E, Ora J, Rogliani P, Matera MG. Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. Respir Med. 2013 Jan;107(1):107-11. doi: 10.1016/j.rmed.2012.09.022. Epub 2012 Oct 18.</citation>
    <PMID>23083839</PMID>
  </reference>
  <reference>
    <citation>Gabrijelcic J, Casas A, Rabinovich RA, Roca J, Barberà JA, Chung KF, Rodríguez-Roisin R. Formoterol protects against platelet-activating factor-induced effects in asthma. Eur Respir J. 2004 Jan;23(1):71-5.</citation>
    <PMID>14738234</PMID>
  </reference>
  <reference>
    <citation>Polverino E, Gómez FP, Manrique H, Soler N, Roca J, Barberà JA, Rodríguez-Roisin R. Gas exchange response to short-acting beta2-agonists in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2007 Aug 15;176(4):350-5. Epub 2007 Apr 12.</citation>
    <PMID>17431221</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2015</study_first_submitted>
  <study_first_submitted_qc>September 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2015</study_first_posted>
  <last_update_submitted>September 10, 2015</last_update_submitted>
  <last_update_submitted_qc>September 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Isabel Blanco</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Indacaterol</keyword>
  <keyword>Pulmonary gas exchange</keyword>
  <keyword>Long-acting bronchodilators</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

